Summit Therapeutics Inc. business relationships
Companies named in Summit Therapeutics Inc.’s 10-K filed 2026-02-23, and public companies whose annual reports name Summit Therapeutics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 19% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 8 / 100
Named in Summit Therapeutics Inc.’s annual report 4
“...e, but are not limited to pumitamig (BNT327), which is owned by BioNTech SE and being developed in a collaboration with Bristol Myers Squibb Co. since June 2025, which has begun conducting Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally, ex-China by...” SEC filing
“...Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally, ex-China by Pfizer Inc. in July 2025, LM-299, which was licensed globally by Merck & Co., Inc. in November 2024, and RC148, which was licensed outside of Greater China by AbbVie Inc. in January 2026.” SEC filing
“...ducting Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally, ex-China by Pfizer Inc. in July 2025, LM-299, which was licensed globally by Merck & Co., Inc. in November 2024, and RC148, which was licensed outside of Greater China by AbbVie Inc. in Januar...” SEC filing
“These include, but are not limited to pumitamig (BNT327), which is owned by BioNTech SE and being developed in a collaboration with Bristol Myers Squibb Co. since June 2025, which has begun conducting Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally,...” SEC filing
Companies whose annual reports name Summit Therapeutics Inc. 2
“...fic product candidates in clinical development for solid tumor indications, including, but not limited to, ivonescimab (Summit Therapeutics Inc.), pumitamig (co-developed by BioNTech SE and Bristol Myers Squibb), LM-299 (LaNova Medicines Ltd.; in-licensed by Merck), SSGJ-707 (3SBio Inc.; in-licensed...” SEC filing
“In June 2025, we entered into a clinical collaboration with Summit Therapeutics, Inc. (Summit) pursuant to which we are evaluating the safety and efficacy, in multiple solid tumor settings, of our clinical-stage RAS(ON) Inhibitors, including daraxonrasib, elironrasib and zoldonrasib, in combination...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.